"A. Okay. Well, I'll just quickly answer the question. I think the dynamics we see right now, biosimilars primarily growth in Europe and Japan. In the US, it continues to be a mixed picture. Of course, hopeful that in our next wave of assets, we can get a much broader set of assets launched in the US, with 15 projects now progressing through our biosimilars portfolio."